Published in J Natl Cancer Inst on July 01, 1992
Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma (2013) 0.89
Head and neck cancer. N Engl J Med (1993) 6.33
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med (1990) 3.69
Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst (1998) 3.17
Retracted Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet (2005) 3.13
Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst (1997) 3.03
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst (2000) 2.39
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst (2000) 2.33
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst (2001) 2.18
Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst (1998) 2.16
Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst (1994) 2.15
Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst (2001) 2.13
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.98
Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer (1998) 1.97
Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys (1991) 1.97
Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res (1997) 1.96
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.81
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res (2000) 1.81
Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst (1997) 1.79
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst (1992) 1.79
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst (1998) 1.78
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst (1993) 1.77
Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med (1995) 1.76
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol (1998) 1.76
Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst (1990) 1.61
Rounded atelectasis and mesothelioma. AJR Am J Roentgenol (1998) 1.60
Effect of age on risk of second primary colorectal cancer. J Natl Cancer Inst (2001) 1.58
Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res (1994) 1.57
The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol (1992) 1.57
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood (1988) 1.55
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst (2001) 1.55
Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med (1991) 1.52
Extraosseous multiple myeloma: imaging features. AJR Am J Roentgenol (1993) 1.52
Genetic factors predisposing to autoimmune diseases. Autoimmune hemolytic anemia, chronic thrombocytopenic purpura, and systemic lupus erythematosus. Am J Med (1982) 1.51
Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev (2000) 1.51
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol (2004) 1.51
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2001) 1.50
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (1999) 1.47
Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer (1995) 1.47
Analysis of clinically occult and mammographically occult breast tumors. AJR Am J Roentgenol (1977) 1.46
Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst (1998) 1.46
Lipoxygenase modulation to reverse carcinogenesis. Cancer Res (2001) 1.46
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol (1993) 1.44
Reduced DNA repair capacity in lung cancer patients. Cancer Res (1996) 1.44
15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst (2000) 1.43
Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res (1993) 1.43
SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol (2001) 1.42
Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene (1999) 1.41
[Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha]. Rev Invest Clin (1994) 1.40
The role of adjuvant surgery in the combined modality therapy of small-cell bronchogenic carcinoma after a chemotherapy-induced partial remission. J Clin Oncol (1990) 1.40
Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys (1995) 1.40
Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am (1997) 1.39
Chemoprevention strategies for lung and upper aerodigestive tract cancer. Cancer Res (1992) 1.39
Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst (1993) 1.38
Molecular markers of the risk of oral cancer. N Engl J Med (2001) 1.38
Proliferation dependence of topoisomerase II mediated drug action. Biochemistry (1986) 1.37
Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med (1994) 1.37
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res (2001) 1.37
Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys (1989) 1.34
Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology (1985) 1.34
Sarcoidosis. Typical and atypical thoracic manifestations and complications. Clin Radiol (1970) 1.34
Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. Clin Radiol (2001) 1.33
Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res (2000) 1.33